Logo Logo

Publications by Dreyling, M.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 33.

Journal article

Rule, S.; Jurczak, W.; Jerkeman, M.; Rusconi, C.; Trneny, M.; Offner, F.; Caballero, D.; Joao, C.; Witzens-Harig, M.; Hess, G.; Bence-Bruckler, I.; Cho, S-G; Thieblemont, C.; Zhou, W.; Henninger, T.; Goldberg, J.; Vermeulen, J.; Dreyling, M. (2018): Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. In: Leukemia, Vol. 32, No. 8: pp. 1799-1803

Dreyling, M.; Morschhauser, F.; Bouabdallah, K.; Bron, D.; Cunningham, D.; Assouline, S. E.; Verhoef, G.; Linton, K.; Thieblemont, C.; Vitolo, U.; Hiemeyer, F.; Giurescu, M.; Garcia-Vargas, J.; Gorbatchevsky, I.; Liu, L.; Koechert, K.; Pena, C.; Neves, M.; Childs, B. H.; Zinzani, P. L. (2017): Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. In: Annals of Oncology, Vol. 28, No. 9: pp. 2169-2178

Seiler, T.; Dreyling, M. (2017): Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives. In: Expert Opinion On investigational Drugs, Vol. 26, No. 8: pp. 909-915

Dreyling, M.; Aukema, S. M.; Rosenwald, A.; Canoni, D.; Rymkiewicz, G.; Thorns, C.; Hartmann, S.; Kluin-Nelemans, H.; Hermine, O.; Klapper, W.; Hoster, E. (2017): P53 but not SOX11 IHC has prognostic value independent of MIPI and Ki-67 in prospective trials of the European-MCL Network. In: Oncology Research and Treatment, Vol. 40: p. 69

Dreyling, M.; Hess, G.; Krekeler, G. (2017): Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice. In: Annals of Oncology, Vol. 28

Liu, L.; Köchert, K.; Seidel, H.; Garcia-Vargas, J.; Childs, B. H.; Follows, G.; Bouabdallah, K.; Dreyling, M.; Pena, C. (2017): Tumor gene expression signatures of BCR/PI3K dependence in association with copanlisib monotherapy activity in heavily pretreated patients with indolent NHL and follicular lymphoma. In: Annals of Oncology, Vol. 28

Provencio Pulla, M.; Santoro, A.; Mollica, L.; Leppa, S.; Follows, G.; Lenz, G.; Kim, W. S.; Nagler, A.; Panayiotidis, P.; Demeter, J.; Ozcan, M.; Kosinova, M.; Bouabdallah, K.; Morschhauser, F.; Ishida, T.; Huang, L.; Garcia-Vargas, J.; Childs, B. H.; Zinzani, P. L.; Dreyling, M. (2017): Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study. In: Annals of Oncology, Vol. 28

Dreyling, M.; Hess, G.; Krekeler, G. (2017): Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice. In: Oncology Research and Treatment, Vol. 40: p. 72

Herold, M.; Hoster, E.; Unterhalt, M.; Hänel, M.; Prange-Krex, G.; Forstpointner, R.; Florschütz, A.; Gräven, U.; Frickhofen, N.; Wulf, G.; Lengfelder, E.; Lerchenmüller, C.; Schlag, R.; Dierlamm, J.; Fischer von Weikersthal, L.; Ahmed, A.; Harich, H.-D.; Rosenwald, A.; Klapper, W.; Dreyling, M.; Hiddemann, W. (2017): Rituximab maintenance versus observation after immunochemotherapy (R-CHOP, R-MCP, R-FCM) in previously untreated follicular lymphoma: a randomized trial of GLSG and OSHO. In: Oncology Research and Treatment, Vol. 40: p. 74

Zinzani, P. L.; Santoro, A.; Leppa, S.; Demeter, J.; Follows, G. A.; Lenz, G.; Kim, W. S.; Mollica, L.; Nagler, A.; Diong, C. P.; Provenciio, M.; Stevens, D. A.; Trevarthen, D.; Maagnoli, M.; Cupit, L.; Yin, S.; Hiemeyer, F.; Garcia-Vargas, J.; Childs, B. H.; Dreyling, M. (2017): Efficacy and safety of Copanlisib in patients with relapsed/refractory follicular lymphoma: a subset analysis of the Chronos-1 study. In: Haematologica, Vol. 102: pp. 314-315

Fischer, L.; Mayer, A.; Irger, M.; Freysoldt, B.; Zimmermann, Y.; Hutter, G.; Hiddemann, W.; Dreyling, M. (2017): CDK4/6-INHIBITION BY ABEMACICLIB INDUCES POTENT EARLY G1-ARREST IN MCL CELL LINES AND SHOWS SEQUENCE-SPECIFIC INTERACTIONS WITH CYTARABINE AND IBRUTINIB. In: Haematologica, Vol. 102: p. 575

Jerkeman, M.; Hallek, M.; Dreyling, M.; Thieblemont, C.; Kimby, E.; Staudt, L. (2017): Targeting of B-cell receptor signalling in B-cell malignancies. In: Journal of internal Medicine, Vol. 282, No. 5: pp. 415-428

Pott, C.; Delfau, M.; Macintyre, E.; Ribrag, V.; Klapper, W.; Unterhalt, M.; Kneba, M.; Hiddemann, W.; Hermine, O.; Kluin-Nelemans, H.; Dreyling, M.; Hoster, E. (2017): Implications of deep molecular response after induction and in maintenance treatment in elderly patients with mantle cell lymphoma: updated results of the randomized EU-MCL elderly trial. In: Oncology Research and Treatment, Vol. 40: p. 13

Dreyling, M.; Campo, E.; Hermine, O.; Jerkeman, M.; Gouill, S. le; Rule, S.; Shpilberg, O.; Walewski, J.; Ladetto, M. (2017): Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. In: Annals of Oncology, Vol. 28: pp. 62-71

Dreyling, M.; Santoro, A.; Mollica, L.; Leppa, S.; Follows, G. A.; Lenz, G.; Kim, W. S.; Nagler, A.; Panayiotidis, P.; Demeter, J.; Ozcan, M.; Kosinova, M.; Bouabdallah, K.; Morschhauser, F.; Stevens, D. A.; Trevarthen, D.; Giurescu, M.; Kupit, L.; Childs, B. H.; Zinzani, P. L. (2017): Copanlisib (COP) in patients with relapsed or refractory indolent B-cell lymphoma: primary results of the pivotal Chronos-1 study. In: Oncology Research and Treatment, Vol. 40: p. 12

Maddocks, K.; Gonzalez Barca, E.; Jurczak, W.; Liberati, A. M.; Duell, J.; Nagy, Z.; Papaj-K, T.; Andre, M.; Kalakonda, N.; Dreyling, M.; Zinzani, P. L.; Ambarkhane, S.; Weirather, J.; Salles, G. (2017): L-Mind: MOR208 Combined with Lenalidomide (Len) In Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R Dlbcl)-A Single-Arm Phase II Study. In: Haematologica, Vol. 102: p. 174

Duell, J.; Gonzalez Barca, E.; Liberati, A. M.; Salles, G.; Gaidano, G.; Jurczak, W.; Nagy, Z.; Papajlk, T.; Andre, M.; Zinzani, P. L.; Kalakonda, N.; Ambarkhane, S.; Weirather, J.; Maddocks, K.; Dreyling, M. (2017): L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) - a single-arm phase II study. In: Oncology Research and Treatment, Vol. 40: p. 68

Younes, A.; Hilden, P.; Coiffier, B.; Hagenbeek, A.; Salles, G.; Wilson, W.; Seymour, J. F.; Kelly, K.; Gribben, J.; Pfreunschuh, M.; Morschhauser, F.; Schoder, H.; Zelenetz, A. D.; Rademaker, J.; Advani, R.; Valente, N.; Fortpied, C.; Witzig, T. E.; Sehn, L. H.; Engert, A.; Fisher, R. I.; Zinzani, P.-L.; Federico, M.; Hutchings, M.; Bollard, C.; Trneny, M.; Elsayed, Y. A.; Tobinai, K.; Abramson, J. S.; Fowler, N.; Goy, A.; Smith, M.; Ansell, S.; Kuruvilla, J.; Dreyling, M.; Thieblemont, C.; Little, R. F.; Aurer, I.; Oers, M. H. J. van; Takeshita, K.; Gopal, A.; Rule, S.; Vos, S. de; Kloos, I.; Kaminski, M. S.; Meignan, M.; Schwartz, L. H.; Leonard, J. P.; Schuster, S. J.; Seshan, V. E. (2017): International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). In: Annals of Oncology, Vol. 28, No. 7: pp. 1436-1447

Ferrero, S.; Pastore, A.; Scholz, C. W.; Forstpointner, R.; Pezzutto, A.; Bergmann, L.; Trümper, L.; Finke, J.; Keller, U.; Ghione, P.; Passera, R.; Hiddemann, W.; Weigert, O.; Unterhalt, M.; Dreyling, M. (2016): Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial. In: Leukemia, Vol. 30, No. 4: pp. 984-987

Tam, C.; Roberts, A.; Anderson, M. A.; Dawson, S. J.; Hicks, R.; Pott, C.; Westerman, D.; Burke, G.; Kamel, S.; Dreyling, M.; Dawson, M.; Seymour, J. (2016): The combination of ibrutinib and venetoclax (ABT-199) rapidly achieves complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study. In: Haematologica, Vol. 101: p. 103

Dreyling, M.; Morschhauser, F.; Bouabdallah, K.; Cunningham, D.; Bron, D.; Linton, K.; Assouline, S.; Verhoef, G.; Thieblemont, C.; Vitolo, U.; Garcia-Vargas, J.; Gorbatchevsky, I.; Neves, M.; Grunert, J.; Hiemeyer, F.; Childs, B. H.; Zinzani, P. L. (2016): Phase 2a study of the Phosphatidylinositol-3-Kinase (PI3K) inhibitor Copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma. In: Haematologica, Vol. 101: p. 104

Lenz, G.; Balasubramanian, S.; Goldberg, J.; Rizo, A.; Schaffer, M.; Phelps, C.; Rule, S.; Dreyling, M. (2016): Sequence variants in patients with primary and acquired resistance to Ibrutinib in the phase 3 MCL3001 (RAY) trial. In: Haematologica, Vol. 101: p. 155

Rule, S.; Dreyling, M.; Hess, G.; Auer, R.; Kahl, B.; Cavazos, N.; Liu, B.; Clow, F.; Goldberg, J.; Beaupre, D.; Vermeulen, J.; Wildgust, M.; Wang, M. (2016): Overall survival outcomes in patients with mantle-cell lymphoma (MCL) treated with Ibrutinib in a pooled analysis of 370 patients from 3 international open-label studies. In: Haematologica, Vol. 101: p. 155

Hutter, G.; Zimmermann, Y.; Zoellner, A.; Irrgang, P.; Arnd, J.; Hiddemann, W.; Dreyling, M. (2016): Mode of action of different PI3K-inhibitors in mantle cell lymphoma. In: Haematologica, Vol. 101: p. 271

Witzens-Harig, M.; Keller, U.; Viardot, A.; Buske, C.; Hönig, E.; Crombe, A.; Brandt, J.; Meissner, J.; Ho, A.; La Rosee, P.; Marks, R.; Dreyling, M.; Hess, G. (2016): Safety and clinical activity of temsirolimus in combination with Rituximab and DHAP in patients with relapsed or refractory diffuse large B-cell lymphoma - preliminary results of the storm trial. In: Haematologica, Vol. 101: p. 390

Dreyling, M.; Krekeler, G.; Neuhof, A.; Woike, M.; Hess, G.; Kalanovic, D. (2016): Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice. In: Annals of Oncology, Vol. 27

Dreyling, M.; Ghielmini, M.; Rule, S.; Salles, G.; Vitolo, U.; Ladetto, M. (2016): Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. In: Annals of Oncology, Vol. 27: v83-v90

Ladetto, M.; Buske, C.; Hutchings, M.; Dreyling, M.; Gaidano, G.; Le Gouill, S.; Luminari, S.; Pott, C.; Zamò, A.; Zucca, E. (2016): ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. In: Annals of Oncology, Vol. 27, No. 12: pp. 2149-2160

Liu, L.; Koechert, K.; Cheng, J.; Garcia-Vargas, J.; Childs, B. H.; Dreyling, M.; Pena, C. (2016): Tumor gene expression profiles associated with single-agent copanlisib activity in heavily pretreated patients with indolent and aggressive non-hodgkin lymphoma (NHL). In: Haematologica, Vol. 101: p. 571

Kvint, R.; Zimmermann, Y.; Hutter, G.; Hiddemann, W.; Dreyling, M. (2016): High efficiency of the pan-PI3K/mTOR inhibitor, PQR-309, in MCL. In: Oncology Research and Treatment, Vol. 39: pp. 153-154

Hutter, G.; Zimmermann, Y.; Bamopoulos, S. A.; Irger, M.; Hiddemann, W.; Dreyling, M. (2016): Synergistic effect of inhibition of multiple PI3K-isoforms due to the differential mode of action of single PI3K-isoform inhibitors in mantle cell lymphoma. In: Oncology Research and Treatment, Vol. 39: p. 154

Dreyling, M.; Krekeler, G.; Neuhof, A.; Woike, M.; Hess, G.; Kalanovic, D. (2016): Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice. In: Oncology Research and Treatment, Vol. 39: p. 156

Al-Sawaf, O.; Kluth, S.; Bahlo, J.; Hopfinger, G.; Fink, A. M.; Cramer, P.; Maurer, C.; Bergmann, M.; Dreyling, M.; Lange, E.; Kneba, M.; Stilgenbauer, S.; Kiehl, M. G.; Jäger, U.; Wendtner, C. M.; Fischer, K.; Hallek, M.; Eichhorst, B. (2016): Impact of gender on outcome after chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustin plus R (BR) in CLL patients: a pooled analysis of the German CLL Study Group (GCLLSG). In: Oncology Research and Treatment, Vol. 39: pp. 212-213

This list was generated on Tue Sep 17 07:18:15 2019 CEST.